Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 3, Mars 2015
Page(s) 241 - 244
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20153103005
Publié en ligne 8 avril 2015
  1. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med 2002 ; 166 : 215–235. [CrossRef] [PubMed]
  2. Borie R, Danel C, Debray MP, et al. Pulmonary alveolar proteinosis. Eur Respir Rev 2011 ; 20 : 98–107. [CrossRef] [PubMed]
  3. Rosen LB, Freeman AF, Yang LM, et al. Anti-GM-CSF autoantibodies in patients with cryptococcal meningitis. J Immunol 2013 ; 190 : 3959–3966. [CrossRef]
  4. Whitsett JA, Wert SE, Weaver TE. Alveolar surfactant homeostasis and the pathogenesis of pulmonary disease. Annu Rev Med 2010 ; 61 : 105–119. [CrossRef] [PubMed]
  5. Stanley E, Lieschke GJ, Grail D, et al. Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994 ; 91 : 5592–5596. [CrossRef]
  6. Shibata Y, Berclaz PY, Chroneos ZC, et al. GM-CSF regulates alveolar macrophage differentiation and innate immunity in the lung through PU.1. Immunity 2001 ; 15 : 557–567. [CrossRef] [PubMed]
  7. Suzuki T, Sakagami T, Young LR, et al. Hereditary pulmonary alveolar proteinosis: pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med 2010 ; 182 : 1292–1304. [CrossRef] [PubMed]
  8. Greenhill SR, Kotton DN. Pulmonary alveolar proteinosis: a bench-to-bedside story of granulocyte-macrophage colony-stimulating factor dysfunction. Chest 2009 ; 136 : 571–577. [CrossRef] [PubMed]
  9. Uchida K, Beck DC, Yamamoto T, et al. GM-CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007 ; 356 : 567–579. [CrossRef] [PubMed]
  10. Michaud G, Reddy C, Ernst A. Whole-lung lavage for pulmonary alveolar proteinosis. Chest 2009 ; 136 : 1678–1681. [CrossRef] [PubMed]
  11. Briens E, Delaval P, Mairesse MP, et al. La protéinose alvéolaire pulmonaire. Rev Mal Respir 2002 ; 19 : 166–182. [PubMed]
  12. Tazawa R, Inoue Y, Arai T, et al. Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy. Chest 2014 ; 145 : 729–737. [CrossRef] [PubMed]
  13. Kavuru MS, Malur A, Marshall A, et al. An open-label trial of rituximab therapy in pulmonary alveolar proteinosis. Eur Respir J 2011 ; 38 : 1361–1367. [CrossRef] [PubMed]
  14. Borie R, Debray V, Laine C, et al. Rituximab therapy in autoimmune pulmonary alveolar proteinosis. Eur Respir J 2009 ; 33 : 1503–1506. [CrossRef] [PubMed]
  15. Ishii H, Seymour JF, Tazawa R, et al. Secondary pulmonary alveolar proteinosis complicating myelodysplastic syndrome results in worsening of prognosis: a retrospective cohort study in Japan. BMC Pulm Med 2014 ; 14 : 37. [CrossRef] [PubMed]
  16. Ishii H, Nakata K, Inoue Y, et al. Clinical course of GM−CSF autoantibody negative pulmonary alveolar proteinosis (NAPAP): efficacy of lavage therapy. Am J Respir Crit Care Med 2009 ; 179 : A3035.
  17. Suzuki T, Sakagami T, Rubin BK, et al. Familial pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 2008 ; 205 : 2703–2710. [CrossRef] [PubMed]
  18. Martinez-Moczygemba M, Doan ML, Elidemir O, et al. Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1. J Exp Med 2008 ; 205 : 2711–2716. [CrossRef] [PubMed]
  19. Dirksen U, Nishinakamura R, Groneck P, et al. Human pulmonary alveolar proteinosis associated with a defect in GM-CSF/IL-3/IL-5 receptor common beta chain expression. J Clin Invest 1997 ; 100 : 2211–2217. [CrossRef] [PubMed]
  20. Hacein-Bey-Abina S, Pai SY, Gaspar HB, et al. A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med 2014 ; 371 : 1407–1417. [CrossRef] [PubMed]
  21. Suzuki T, Arumugam P, Sakagami T, et al. Pulmonary macrophage transplantation therapy. Nature 2014 ; 514 : 450–454. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.